Eraaya Lifespaces revises EGM notice for preferential issue and RPTs
Eraaya Lifespaces Limited issued a corrigendum on June 04, 2026, updating the notice for its EGM on June 08, 2026. The filing details a preferential issue of warrants valued at ₹31.53 per share, with proceeds of ₹99.97 crore allocated for working capital, investments, and general corporate purposes. It also outlines material related party transactions with Ebix group subsidiaries and promoter group entities Vikas Lifecare Limited and Advik Capital Limited, seeking shareholder approval for the financial year 2026-27.

*this image is generated using AI for illustrative purposes only.
Eraaya Lifespaces Limited has issued a corrigendum to its Extra-Ordinary General Meeting (EGM) notice on June 04, 2026, to incorporate additional disclosures regarding a proposed preferential issue of securities and related party transactions. The company seeks shareholder approval for these items at the EGM scheduled for June 08, 2026. The update provides specific details on valuation, fund utilization, and the rationale for transactions with related parties, including subsidiaries and entities under the Ebix group.
Preferential Issue Valuation and Objects
The company has obtained a valuation report from Mr. Manish Manwani, an independent Registered Valuer, determining the price for the preferential issue at ₹31.53 per equity share. This valuation supports the issuance of equity shares for consideration other than cash and the issuance of up to 3,12,41,250 Fully Convertible Warrants on a preferential basis to promoter and non-promoter categories. A compliance certificate from M/s. Prachi Bansal & Associates, Practicing Company Secretary, has also been obtained confirming adherence to Chapter V of the SEBI ICDR Regulations.
Utilization of Issue Proceeds
Eraaya Lifespaces intends to utilize the proceeds from the preferential issue of warrants totaling ₹99.97 crore across specific objects by March 31, 2028. The deployment of funds is contingent upon 100% conversion of the warrants into equity shares within the stipulated time. As the issue size is less than ₹100 crore, the company is not required to appoint a credit rating agency as a monitoring agency under Regulation 162A of the SEBI ICDR Regulations.
| S.No. | Particulars | Total estimated amount to be utilized (Rs. in Crores) | Tentative timeline for utilization of funds |
|---|---|---|---|
| 1 | Working Capital Requirements | 50.00 | Up to 31 March 2028 |
| 2 | Investments in subsidiaries, step-down subsidiaries, joint ventures, and associates | 25.00 | Up to 31 March 2028 |
| 3 | General Corporate Purposes | 24.50 | Up to 31 March 2028 |
| 4 | Issue related expenses | 0.47 | Up to 31 March 2028 |
| Total | 99.97 |
Related Party Transactions
The company is seeking approval for material related party transactions with subsidiaries and step-down subsidiaries operating under the Ebix group, including entities such as Ebix Technologies Limited, EbixCash World Money Limited, and Ebix Inc. These transactions involve operational, financial, and commercial support, including inter-corporate deposits, loans, and shared services. The Audit Committee and the Board of Directors reviewed and approved these transactions on May 11, 2026, determining them to be commercially beneficial and in the interest of the company.
Transactions with Vikas Lifecare Limited and Advik Capital Limited, entities sharing the same promoter group, are also proposed for approval. These relate to financial and business support transactions received during the acquisition of Ebix group businesses. The proposed transactions for the financial year 2026-27 are considered material relative to the company's annual consolidated turnover, with specific percentages disclosed for each related party.
Historical Stock Returns for Eraaya Lifespaces
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.16% | -9.38% | -8.74% | -23.80% | -36.90% | +3,844.44% |
What are the potential risks if the preferential warrants are not converted into equity shares by the stipulated deadline?
How will the substantial allocation for general corporate purposes impact shareholder value in the long term?
What specific strategic milestones does the company aim to achieve by investing ₹25 crore in subsidiaries and joint ventures?


































